Fox Chase Cancer Center

Georgetown University

Institute for Cancer Research

The General Hospital Corporation

Nexuspharma, Inc.

Ilya G Serebriiskii

Erica A Golemis

Louis M Weiner

Igor Astsaturov

Vladimir Khazak

J Keith Joung

Robert R Clarke

Greg H Enders

Sanjeevani Arora

Emmanuelle Nicolas

Andrew Godwin

Vladimir Ratushny

Rochelle E Nasto

Keith J Joung

Systems and methods for mitigating prostate cancer development are provided. Peripheral blood cells may be evaluated for the presence or quantity of gamma-H2AX foci, and/or for gene alterations encoding a protein with impaired or lack of function, for example, because the encoded protein is truncated, and correlating with prostate cancer development. Such nucleic acids may encode proteins from or peripheral to the DNA damage repair pathway and/or androgen receptor signaling pathway, or that are otherwise correlated with prostate cancer development. Such genes include one or more of AKR1C1, PALB2, APTX, BLM, BRCA1, CTBP1, DDB2, FANCA, FANCL, MBD5, MSH3, NEIL3, RAD51D, RAD54L2, SP1, TP53BP1, UBE2D3, UBE2V2, NRIP1, EFCAB6, CRISP3, PAPSS2, ATP6V0A2, ALG13, MGAT2, B3GAT3, DOLK, FLT3, ASXL1, KDR, or NOTCH2.

Systems and methods for treating patients having a genetic predisposition to develop prostate cancer

Compositions and methods for the treatment and diagnosis of cancer are disclosed.

EGFR/NEDD9/TGF-&#x3b2; interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders

Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.

C-Myc as a biomarker for tumor sensitivity to treatment with RNA polymerase II inhibition

The invention relates to methods of inhibiting the growth or proliferation of a cell, the method comprising reducing the expression or activity of at least one gene in the cell selected from the group consisting of BLOC1S1, CDC2L1, CNOT1, DDX54, EIF3I, FANCG, FBP1, IER2, KIF1A, LCK, NR2F1, PNRC1, POLR2A, POLR2B, POLR2C, PRPF6, PSMB4, PSMC5, PSMD1, RPS2, SCNN1A, SF3A3, TAF2, TOB1 and TSC22D4.

Methods of inhibiting proliferation of estrogen-independent cancer cells

Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.

Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer

A combined yeast/bacterial two-hybrid system is disclosed.

Yeast bacterial two-hybrid system and methods of use thereof

The present invention provides an improved yeast interaction trap method and reagents for the detection of novel protein-protein interactions. The invention comprises a dual bait system which improves the accuracy of library screens with an immediate selection to eliminate false positives. The dual bait system of the present invention also allows for comparative, simultaneous assessment of interactions between two related members of a protein family or a wild-type versus mutated form of the same protein.

Growing community of inventors

Rockledge, PA, United States of America

Ilya G Serebriiskii